• January 26, 2023

This Week In Credit Card News: A Beneficial Change In Credit Scoring; Big Banks To Develop New Digital Wallet

Banks Plan Payment Wallet to Compete With PayPal, Apple Pay Big banks are teaming up to launch a digital wallet that people can use to shop online. Wells Fargo, Bank of …

Zoho – Running A Software Enterprise From A Village

If you have read my articles, you will know I like many things about Zoho; the company, the product approach, and innovation. Zoho has a track record of recognizing opportunities and …

Hybrid And Beyond: Is “Flexible Working” Helping Britain’s SMEs To Deal With Wage Pressures?

It sounds like a straightforward and wholly logical proposition. The United Kingdom is facing a shortfall in labor. Even against a backdrop of static or negative growth, there are around one …

Abbott Laboratories reported $1 billion in fourth quarter profits despite an “expected year-over-year decline in Covid-19 testing-related sales,” the company said.

Abbott, which has been one of the world’s biggest makers and suppliers of diagnostic tests for Covid-19 during the global pandemic, reported an adjusted fourth-quarter profit of $1.03 billion, or $1.03 per share, which beat Wall Street analysts forecasts.

Fourth quarter sales fell 12% from a year earlier to $10 billion from $11.5 billion in the year-ago quarter thanks to the dip in sales of Covid tests and loss of revenue from the nutritional business as a result of a high profile manufacturing disruption at Abbott’s Sturgis, Mich., facility last year.

Advertisement

Abbott, however, said its underlying diversified portfolio of businesses, including established pharmaceuticals and medical devices including its top-selling glucose monitoring device FreeStyle Libre remain strong. “Excluding COVID-19 testing-related sales and U.S. infant formula sales that were impacted by manufacturing disruptions, full-year 2022 sales increased 1.9 percent on a reported basis and 7.4 percent on an organic basis,” Abbott said in its fourth quarter and full year 2022 earnings report released Wednesday.

Abbott said worldwide Covid-19 testing-related sales were $1.069 billion in the fourth quarter of 2022 compared to $2.3 billion in the fourth quarter of 2021. And for the full year 2022, Abbott said worldwide Covid-19 testing related sales were $8.36 billion compared to $7.7 billion in the prior year.

“We significantly exceeded the EPS guidance we provided at the beginning of last year despite challenging global business conditions,” Abbott chairman and chief executive Robert B. Ford said.

Advertisement

Leave a Reply

Your email address will not be published.